CAPR · trading date Oct 9, 2026 · previous close $8.01 · source: Alpaca (IEX feed, not consolidated full-market data).
Key Financials
Revenue
$0
Net income
-$105.04M
Total assets
$355.95M
Total liabilities
$50.16M
Stockholders' equity
$305.79M
Cash & equivalents
$287.85M
Operating income
-$108.14M
Operating cash flow
-$69.81M
Capital expenditures
$2.90M
Fiscal year 2025, via 10-K filed 2026-03-17.
A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$72.72M
Free cash flow margin
—
Liabilities / assets
14.1%
Equity / assets
85.9%
CapEx / revenue
—
Operating cash flow / net income
0.66×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
San Diego, CA 92121
10865 ROAD TO THE CURE
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:15 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.